文献速递脑血管病神经重症与神经感染癫痫

纽约市住院COVID-19患者神经障碍的前瞻性研究

A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City.
PubMed 文献 · Neurology · 2020-10-05

结果显示13.5%患者出现新发神经障碍,以中毒/代谢性脑病最常见,且神经障碍与住院死亡风险增加及出院回家可能性降低独立相关。

要点

  • 住院COVID-19患者中新发神经障碍发生率为13.5%,中位出现时间为症状起始后2天。
  • 最常见诊断包括中毒/代谢性脑病、癫痫发作、卒中和缺氧/缺血性损伤。
  • 调整混杂因素后,神经障碍与住院死亡风险增加(HR 1.38)及出院回家可能性降低(HR 0.72)相关。

核心结论

  • 住院COVID-19患者中新发神经障碍发生率为13.5%,与住院死亡风险增加和出院回家可能性降低独立相关。
  • 许多观察到的神经障碍可能是严重全身性疾病的后遗症。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入纽约大都市区连续住院的实验室确诊SARS-CoV-2感染成人患者。
  • 共纳入4491例住院COVID-19患者,由神经科医生诊断并记录新发神经障碍,比较有无神经障碍患者的住院死亡率和出院去向。

主要发现

  • 4491例患者中606例(13.5%)出现新发神经障碍,中位出现时间为COVID-19症状起始后2天。
  • 最常见诊断:中毒/代谢性脑病6.8%、卒中1.9%、癫痫发作1.6%、缺氧/缺血性损伤1.4%。
  • 无患者出现归因于SARS-CoV-2感染的脑膜炎/脑炎或脊髓病/脊髓炎,18份脑脊液标本SARS-CoV-2逆转录PCR均为阴性。
  • 神经障碍患者更常见高龄、男性、白人、高血压、糖尿病、插管且SOFA评分更高(所有p<0.05)。
  • 调整年龄、性别、SOFA评分、插管、病史、内科并发症、药物及舒适照护状态后,神经障碍患者住院死亡风险增加(HR 1.38,95%CI 1.17-1.62,p<0.001),出院回家可能性降低(HR 0.72,95%CI 0.63-0.85,p<0.001)。

关键数值与推荐

  • 新发神经障碍总体发生率为13.5%(606/4491)。
  • 中毒/代谢性脑病发生率6.8%,卒中1.9%,癫痫发作1.6%,缺氧/缺血性损伤1.4%。
  • 神经障碍与住院死亡风险增加相关:HR 1.38(95%CI 1.17-1.62,p<0.001)。
  • 神经障碍与出院回家可能性降低相关:HR 0.72(95%CI 0.63-0.85,p<0.001)。

临床怎么用

  • 住院COVID-19患者应警惕新发神经障碍,尤其高龄、男性、高血压、糖尿病及高SOFA评分者。
  • 出现神经障碍提示住院死亡风险增加和出院回家可能性降低,需加强监测与康复规划。
  • 脑脊液SARS-CoV-2 PCR阴性及无脑炎/脊髓炎表现提示多数神经障碍可能继发于全身性疾病而非直接中枢感染。

局限性

  • 观察性研究设计无法确立神经障碍与不良结局的因果关系。
  • 研究纳入连续住院成人患者,结果可能不适用于非住院或轻症患者。
  • 神经障碍诊断依赖神经科医生评估,可能存在诊断偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the prevalence and associated mortality of well-defined neurologic diagnoses among patients with coronavirus disease 2019 (COVID-19), we prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients and recorded new neurologic disorders and hospital outcomes. METHODS: We conducted a prospective, multicenter, observational study of consecutive hospitalized adults in the New York City metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between patients with COVID-19 with and without neurologic disorders. RESULTS: Of 4,491 patients with COVID-19 hospitalized during the study timeframe, 606 (13.5%) developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset. The most common diagnoses were toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). No patient had meningitis/encephalitis or myelopathy/myelitis referable to SARS-CoV-2 infection and 18/18 CSF specimens were reverse transcriptase PCR negative for SARS-CoV-2. Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment (SOFA) scores (all p < 0.05). After adjusting for age, sex, SOFA scores, intubation, history, medical complications, medications, and comfort care status, patients with COVID-19 with neurologic disorders had increased risk of in-hospital mortality (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.17-1.62, p < 0.001) and decreased likelihood of discharge home (HR 0.72, 95% CI 0.63-0.85, p < 0.001). CONCLUSIONS: Neurologic disorders were detected in 13.5% of patients with COVID-19 and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Frontera JA, Sabadia S, Lalchan R, et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City. Neurology. 2020. PMID: 33020166. doi:10.1212/WNL.0000000000010979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。